Onkologie. 2018:12(6):273-277 | DOI: 10.36290/xon.2018.049

Fertility-sparing management in women with endometrial and ovarian cancers

Pavla Svobodová
Gynekologická klinika 3. LF UK a ÚVN-VoFN, Praha

The trend of postponing pregnancy to older age increases the risk of developing malignancies before fulfilling reproduction plans.A non-negligible number of women who are in their fertile age and still have no children suddenly face a situation of receivinga diagnosis of reproductive organ malignancy. Protection of fertility in young women is one of the important parts of treatmentmanagement. Of foremost importance is the oncological treatment outcome; hence, indications to fertility-sparing managementare narrowed down to the population of younger women with early-stage, low-grade tumours who are very strongly motivated.Fertility-sparing management in gynaecological malignancies is possible, but under precisely defined conditions. Intensivefollow-up after completion of conservative treatment is essential for all patients who receive it since the risk of recurrence is real.The benefits, risks, and safety of treatment should remain balanced.

Keywords: endometrial cancer, ovarian cancer, fertility-sparing surgery, conservative treatment, hormone therapy, oncofertility

Published: December 15, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svobodová P. Fertility-sparing management in women with endometrial and ovarian cancers. Onkologie. 2018;12(6):273-277. doi: 10.36290/xon.2018.049.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Frühaufová K, Hulvert J. Zachování fertility u onkologicky nemocných. Grada 2017.
    2. Lee S, Kim SK, Hwang KJ, et al. Fertility preservation for patients with gynecologic malignancies: The Korean Society for fertility preservation clinical guidelines. Clin Exp Reprod Med 2017; 44(4): 175-180. Go to original source... Go to PubMed...
    3. Brännström M, Johanesson L, Dahm-Kähler P, et al. First clinical uterus transplantation trial: a six-month report. Fertil Steril 2014; 101: 1228-1236. Go to original source... Go to PubMed...
    4. Novotvary 2015, ÚZIS ČR
    5. Lee NK, Cheung MK, Shin JY, et al. Prognostic factors for uterine cancer in reproductive-age women. Obstet Gynecol 2007;109: 655-662. Go to original source... Go to PubMed...
    6. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. J Epidemiol Biostat 2001; 6: 47-86. Go to PubMed...
    7. Crissman JD, Azoury RS, Barnes AE, et al. Endometrial carcinoma in women 40 years of age or younger. Obstet Gynecol 1981; 57: 699-704. Go to PubMed...
    8. Rodolakis A, Biliatis I, Morice P, et al. European Society of Gynecologic Oncology Task Force for Fertility Preservation. Clinical recommendations for fertility-sparing management in young endometrial cancer patients. Int J Gynecol Cancer 2015; 25: 1258-1265. Go to original source... Go to PubMed...
    9. Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase II study of fertility-sparing treatment wit medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007; 25: 2798-2803. Go to original source... Go to PubMed...
    10. Kinkel K, Kaji Y, Yu KK, et al. Radiologic staging in patients with EC: a meta-analysis. Radiology 1999; 212: 711-718. Go to original source... Go to PubMed...
    11. Signorelli M, Caspani G, Bonazzi C, et al. Fertility-sparing treatment in young women with EC or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. BJOG 2009; 116: 114-118. Go to original source... Go to PubMed...
    12. Laurelli G, Di Vagno G, Scaffa C, et al. Conservative treatment of early EC: preliminary results of a pilot study. Gynecol Oncol 2011; 120: 43-46. Go to original source... Go to PubMed...
    13. Yamazawa K, Hirai M, Fujito A, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 2007; 22: 1953-1958. Go to original source... Go to PubMed...
    14. Kim MK, Seong SJ, LeeTS, et al. Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early stage EC in young women: single-arm, prospective multicenter study: Korean gynecologic oncology group (KGOG 2009). Jpn J Clin Oncol 2012.42: 1215-1218. Go to original source... Go to PubMed...
    15. Koskas M, Uzna J, Luton D, et al. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril 2014;101: 785-794. Go to original source... Go to PubMed...
    16. Kim MK, Seong SJ, Song T, et al. Comparison of dilation & curettage and endometrial aspiration biopsy accuracy in patiens treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer. Gynecol Oncol 2013; 130: 470-473. Go to original source... Go to PubMed...
    17. Gallos ID, Yap J, Rajkowa M, et al. Regression, relapse, and live birth rates with fertility sparing therapy for EC and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012; 207: 266.e1-266.e2 Go to original source... Go to PubMed...
    18. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Radiother Oncol. 2015 Dec; 117(3): 559-581. doi: 10.1016/j.radonc.2015.11.013. Epub 2015 Dec 9. Go to original source... Go to PubMed...
    19. Park JY, Nam JH. Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. Oncologist. 2015 Mar; 20(3): 270-278. doi: 10.1634/theoncologist.2013-0445. Epub 2015Feb 11. Go to original source... Go to PubMed...
    20. Tomao F, Peccatori F, del Pup L, et al. Special issues in fertility preservation for gynecologic malignancies. Crit Rev Onc 2016; 97: 206-219. Go to original source... Go to PubMed...
    21. Park JY, Kim DY, Kim JH, et al. Long-term oncologic outcomes after fertility-sparing management using oral progestins for young women with EC (KGOG 2002). Eur J Cancer 2013. 49: 868-874. Go to original source... Go to PubMed...
    22. Gunderson CC, Fader AN, Carson KA, et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012; 125:477-482. Go to original source... Go to PubMed...
    23. Park JY, Seong SJ, Kim TJ, et al. Pregnancy outcomes after fertility-sparing management in young women with early EC. Obstet Gynecol 2013; 121: 136-142. Go to original source... Go to PubMed...
    24. Svobodová P. Fertilitu šetřicí léčba u žen s karcinomem endometria. Prakt Gyn 2016; 20(1): 19-22.
    25. Morice P, Denschlag D, Rodolakis A, et al. Fertility Task Force of the European Society of Gynecologic Oncology. Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. Int J Gynecol Cancer. 2011 Jul; 21(5): 951-963. doi: 10.1097/IGC.0b013e31821bec6b. Go to original source... Go to PubMed...
    26. Zikán M, Cibula D, Fischerová, et al. Guideline gynekologických zhoubných nádorů: Standard - Komplexní léčba ovariálních epiteliálních zhoubných nádorů. 2013 www.onkogynekologie.com
    27. Nasoudis D, Chapman-Davis E, et al. Could fertility-sparing surgery be considered for women with early stage ovarian cear cell carcinoma? J Gynecol Oncol. 2017; 28(6):e71 Go to original source... Go to PubMed...
    28. Ditto A, Martinelli F, Bogani G, et al. Lonf-term safety of fertility sparing surgery in early stage ovarian cancer: comparison to standard radical surgical procedures. Gynecol Oncol 2015; 138: 78-82. Go to original source... Go to PubMed...
    29. Bentivegna E, Gouy S, Maulard A, et al. Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues. Ann Oncol. 2016 Nov; 27(11): 1994-2004. Epub 2016 Aug 8. Go to original source... Go to PubMed...
    30. Zanetta G, Chiari S, Rota S, et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol. 1997 Sep; 104(9): 1030-1035. Go to original source... Go to PubMed...
    31. Benjamin I, Morgan MA, Rubin SC. Occult bilateral involvement in stage I epithelial ovarian cancer. 1999 Gynecol Oncol 72: 288-291. Go to original source... Go to PubMed...
    32. Fruscio R, Ceppi L, Corso S, et al. Long-term results of fertility sparing treatment compared with standard radical surgery for early stage epithelial ovarian cancer. BJC 2016; 115: 641-648. Go to original source... Go to PubMed...
    33. Zapardiel I, Diestro MD, Aletti G. Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes. Eur J Surg Oncol. 2014; 40(4): 387-393. doi: 10.1016/j.ejso.2013.11.028. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.